Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial
Open Access
- 31 July 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 55 (10), 2794-2799
- https://doi.org/10.1007/s00125-012-2658-2
Abstract
Aims/hypothesis Recent reports of decreased capillary density in the adipose tissue of obese individuals suggest that an imbalance of angiogenesis and adipogenesis may, in part, underlie insulin resistance. This study aimed to determine whether the insulin-sensitising peroxisome proliferator-activated receptor γ (PPARγ) activator rosiglitazone affects adipose tissue vascularisation in normal humans. Methods A randomised, parallel-group, investigator-blinded placebo-controlled trial was conducted with normoglycaemic volunteers with BMI 27–43, recruited from the community at the University of Massachusetts Medical School, Worcester, MA, USA. Peri-umbilical adipose tissue biopsies were obtained before and after treatment for 6 weeks with rosiglitazone (8 mg once daily) or placebo, which were randomly allocated from a sequentially numbered list. The primary outcomes were adipocyte size and capillary density measured by immunohistochemistry, and angiogenic potential assessed by capillary sprout formation in Matrigel. Secondary outcomes were serum adiponectin, glycaemic, lipid and liver function variables. Results A total of 35 individuals fulfilling the inclusion criteria were randomised, and complete before-vs-after analyses were achieved in 30 participants (13 and 17, placebo and rosiglitazone, respectively). Significant differences, assessed by paired two-tailed Student t tests, were seen in response to rosiglitazone for adipocyte size (3,458 ± 202 vs 2,693 ± 223 μm2, p = 0.0049), capillary density (5.6 ± 0.5 vs 7.5 ± 0.5 lumens/field, p = 0.0098), serum adiponectin (14.3 ± 1.5 vs 28.6 ± 3.0 ng/ml, p < 0.0001) and alkaline phosphatase (1.04 ± 0.07 vs 0.87 ± 0.05 μkat/l, p = 0.001). A difference in angiogenic potential before and after treatment between the placebo and rosiglitazone groups was also seen (−23.88 ± 14 vs 13.42 ± 13, p = 0.029, two-tailed Mann–Whitney test). Conclusions/interpretation Significant effects on adipose tissue vascular architecture occur after a short period of treatment with rosiglitazone in individuals with normal glucose tolerance. Improved adipose tissue vascularisation may, in part, mediate the therapeutic actions of this class of drugs. Trial registration ClinicalTrials.gov NCT01150981 Funding The study was funded by National Institutes of Health grant DK089101 to S. Corvera, and by pilot funding from the University of Massachusetts (UMASS) Center for Clinical Translational Sciences (M. Thompson, S. Malkani and S. Corvera). Morphology core services were supported by UMASS Diabetes Endocrine Research Center (DERC) grant DK32520.Keywords
This publication has 10 references indexed in Scilit:
- Adipose Tissue Extracellular Matrix and Vascular Abnormalities in Obesity and Insulin ResistanceJournal of Clinical Endocrinology & Metabolism, 2011
- Increased Adipose Tissue Oxygen Tension in Obese Compared With Lean Men Is Accompanied by Insulin Resistance, Impaired Adipose Tissue Capillarization, and InflammationCell Metabolism, 2011
- Depot-Specific Differences and Insufficient Subcutaneous Adipose Tissue Angiogenesis in Human ObesityCirculation, 2011
- ORIGINAL ARTICLE: Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2‐year follow‐up studyClinical Endocrinology, 2010
- Fibrosis in Human Adipose Tissue: Composition, Distribution, and Link With Lipid Metabolism and Fat Mass LossDiabetes, 2010
- Adipose Tissue Endothelial Cells From Obese Human Subjects: Differences Among Depots in Angiogenic, Metabolic, and Inflammatory Gene Expression and Cellular SenescenceDiabetes, 2010
- Proangiogenic Contribution of Adiponectin toward Mammary Tumor Growth In vivoClinical Cancer Research, 2009
- Reduced Adipose Tissue Oxygenation in Human ObesityDiabetes, 2009
- Enhanced angiogenesis in obesity and in response to PPARγ activators through adipocyte VEGF and ANGPTL4 productionAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.JCI Insight, 1998